Pharmaceuticals, Biotechnology and Life Sciences
Study Demonstrates RiskScore as a More Accurate Predictor of Breast Cancer Risk, Doubling Accuracy Compared to the Tyrer-Cuzick ModelSALT LAKE…
– The Company will focus resources on advancing its lead asset, PYX-201 – PYX-201 is a novel first-in-concept antibody-drug conjugate…
AUSTIN, Texas, Dec. 19, 2024 (GLOBE NEWSWIRE) — Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM” or the “Company”), a…
Webcast Scheduled for Thursday, January 2 at 4:30 p.m. EasternCHASKA, Minn., Dec. 19, 2024 (GLOBE NEWSWIRE) — Lifecore Biomedical, Inc.…
Tokyo, Japan and Cambridge, UK, 19 December 2024 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) –…
RYONCIL (remestemcel-L) is the first MSC product approved by FDA for any indication.RYONCIL is the first FDA-approved therapy for children…
Files Definitive Proxy Statement and Mails Letter to StockholdersTUSTIN, Calif., Dec. 18, 2024 (GLOBE NEWSWIRE) — Avid Bioservices, Inc. (NASDAQ:…
VANCOUVER, British Columbia, Dec. 17, 2024 (GLOBE NEWSWIRE) — Rakovina Therapeutics Inc. (“Rakovina” or the “Company”) (TSX-V: RKV) announces that…
A Plan for Compliance has been UndertakenOCALA, Fla., Dec. 17, 2024 (GLOBE NEWSWIRE) — AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM”…
Participants can register here for the virtual event airing 9:00am ET / 3:00pm CET PARIS and CAMBRIDGE, Mass., Dec. 17,…